Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Añadir filtros








Intervalo de año
1.
The Ewha Medical Journal ; : 50-54, 2017.
Artículo en Inglés | WPRIM | ID: wpr-95356

RESUMEN

Constipation is a prevalent, often chronic, gastrointestinal motility disorder. Bisacodyl, a stimulant laxative, is widely used to treat constipation in adults and children. This drug is usually safe, but it has some side effects including diarrhea, abdominal pain, colitis, and proctitis. There have been reports that rectal administration of bisacodyl could cause injury to the rectal mucosa by mechanical and chemical mechanisms. However, there has been no report of severe proctitis with rectal ulcers in patients taking oral bisacodyl. In this report, we describe the case of an 80-year-old woman with severe rectal ulcers and proctitis after taking oral bisacodyl for several days, and review the literature.


Asunto(s)
Adulto , Anciano de 80 o más Años , Niño , Femenino , Humanos , Dolor Abdominal , Administración Rectal , Bisacodilo , Colitis , Estreñimiento , Diarrea , Motilidad Gastrointestinal , Membrana Mucosa , Proctitis , Recto , Úlcera
2.
Korean Journal of Medicine ; : 625-629, 2014.
Artículo en Coreano | WPRIM | ID: wpr-140467

RESUMEN

Hypokalemic periodic paralysis is a rare disorder characterized by sudden onset of weakness and low serum potassium levels. We report a case provoked by combination chemotherapy including prednisolone. A 23-yr-man, diagnosed with diffuse large B-cell lymphoma, received chemotherapy. He developed significant weakness in upper and lower extremities during chemotherapy, and his serum potassium level was 1.7 mmol/L. Potassium replacement restored the weakness. Further workup revealed that prednisolone had provoked hypokalemic paralysis. As prednisolone triggered an attack of hypokalemic periodic paralysis, it should be administered with caution, particularly in patients with periodic paralysis.


Asunto(s)
Humanos , Quimioterapia , Quimioterapia Combinada , Parálisis Periódica Hipopotasémica , Extremidad Inferior , Linfoma de Células B , Parálisis , Potasio , Prednisolona
3.
Korean Journal of Medicine ; : 625-629, 2014.
Artículo en Coreano | WPRIM | ID: wpr-140466

RESUMEN

Hypokalemic periodic paralysis is a rare disorder characterized by sudden onset of weakness and low serum potassium levels. We report a case provoked by combination chemotherapy including prednisolone. A 23-yr-man, diagnosed with diffuse large B-cell lymphoma, received chemotherapy. He developed significant weakness in upper and lower extremities during chemotherapy, and his serum potassium level was 1.7 mmol/L. Potassium replacement restored the weakness. Further workup revealed that prednisolone had provoked hypokalemic paralysis. As prednisolone triggered an attack of hypokalemic periodic paralysis, it should be administered with caution, particularly in patients with periodic paralysis.


Asunto(s)
Humanos , Quimioterapia , Quimioterapia Combinada , Parálisis Periódica Hipopotasémica , Extremidad Inferior , Linfoma de Células B , Parálisis , Potasio , Prednisolona
4.
Journal of Korean Diabetes ; : 178-184, 2014.
Artículo en Coreano | WPRIM | ID: wpr-726964

RESUMEN

Atypical antipsychotics, which have better efficacy and fewer side effects compared to first-generation antipsychotics, are being used increasingly for the treatment of schizophrenia. However, adverse events such as weight gain, diabetes mellitus and abnormal lipid profile have been reported in patients treated with these agents. Diabetic ketoacidosis (DKA) is a rare side effect of atypical antipsychotics, but deserves attention due to its severity. Although various atypical antipsychotics have been reported as causing DKA, there have been no reports showing an association with DKA and paliperidone, which is a recently developed antipsychotic agent. Here, we report two cases of DKA in patients with paliperidone therapy. Both cases had no history of diabetes before use of paliperidone, and DKA was manifested within 2 years of starting paliperidone therapy. Like other atypical antipsychotics, use of paliperidone warrants monitoring for metabolic derangements including DKA.


Asunto(s)
Humanos , Antipsicóticos , Diabetes Mellitus , Cetoacidosis Diabética , Esquizofrenia , Aumento de Peso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA